Dear Dr Yong H. Rho, I am impressed by your work and company. I notoce that you take a pharma regulatory path for your compounds, which makes perfect sense of course. I wonderede whether you also have natural compounds in your pipeline that could follow a food regulatory pathway (shorter, less expensive; but also lower reward). For clinically validated food related compounds DSM Venturing would be interested to discuss further, eg with the perspective of an equity investment in case data are convincing. Can you comment? Look forward hearing from you, best regards, Dr Marcel Kloosterman, Investment manager, DSM Venturing
Obetat Biopharma 
Dear Dr Yong H. Rho, I am impressed by your work and company. I notoce that you take a pharma regulatory path for your compounds, which makes perfect sense of course. I wonderede whether you also have natural compounds in your pipeline that could follow a food regulatory pathway (shorter, less expensive; but also lower reward). For clinically validated food related compounds DSM Venturing would be interested to discuss further, eg with the perspective of an equity investment in case data are convincing. Can you comment? Look forward hearing from you, best regards, Dr Marcel Kloosterman, Investment manager, DSM Venturing